Clinical Characteristics of Peripheral Hemogram and DNMT3A Gene Mutation in Patients with Primary AML Treated by FLT3-ITD-mt and FLT3-ITD-wt.
10.7534/j.issn.1009-2137.2019.06.018
- Author:
Jing-Dong LI
1
;
Xiao-Lin HAN
2
,
3
;
Cui YANG
1
;
Ang LI
4
Author Information
1. Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, Henan Province, China.
2. Department of Hematology, The First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, Henan Province, China,E-mail: xykljd@
3. com.
4. Queen Mary College, Nanchang University, Nanchang 33000, Jiangxi Province, China.
- Publication Type:Journal Article
- MeSH:
DNA (Cytosine-5-)-Methyltransferases;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
Mutation;
Retrospective Studies;
Transplantation Conditioning;
fms-Like Tyrosine Kinase 3
- From:
Journal of Experimental Hematology
2019;27(6):1820-1824
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).
METHODS:The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep. 2018 in the department of hematology, aerospace center hospital were retrospectively analyzed. Complications and disease-free survival after HSCT were observed.
RESULTS:All the patients could well tolerate the conditioning regimen and acquired hematopoietic recon-struction. Following up till December 2018, with a median time of 11.5 months (1-51); acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases, Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival. The longest disease-free survival time has reached 51 months.
CONCLUSION:allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-cell lymphoma, which can be chosen as salvage treatment method for patients with primary resistance. Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.
